Transcript - Q1 Earnings Conference Call- FY 2026-27

AI summary - Q1 FY27 total income INR1,129 million +13.7% y-y; EBITDA INR411 million +16% y-y; EBITDA margin 36.4%; PAT INR210 million +11.4% y-y; PAT margin 18.6% - Pharma contract research and testing showed stable sequential revenue with strong y-y growth; clinical research recovering - Food testing declined due to global import-export challenges; focus shifted to domestic market - Electronics testing stable; defense budget increase of 15.19% expected to boost demand - Biologics vertical operational with first order secured; commercialization started in Q1 - Capex planned INR80 crores for FY27, including INR10 crores remaining for biologics - Export revenue contribution about 40%, mainly from US pharma services - Management confident on maintaining growth momentum despite near-term headwinds - Customer retention rate above 90%; infrastructure capacity built for next 4-5 years - Margins expected to sustain; operating margin moderated q-o-q due to facility expenses and currency appreciation